Structure-activity relationship of a glycolipid, sulfoquinovosyl diacylglycerol, with the DNA binding activity of p53

HIROSHI IIJIMA1, NOBUYUKI KASAI2, HIROYUKI CHIKU2, TOSHIFUMI TAKEUCHI2, KOUJI KURAMOCHI2, SHINYA HANASHIMA2, SUSUMU KOBAYASHI3,4, FUMIO SUGAWARA2,4, KENGO SAKAGUCHI2,4, HIROMI YOSHIDA1,5 and YOSHIYUKI MIZUSHINA1,5

1Laboratory of Food and Nutritional Sciences, Department of Nutritional Science, Kobe-Gakuin University, Nishi-ku, Kobe, Hyogo 651-2180; 2Department of Applied Biological Science, Faculty of Science and Technology; 3Faculty of Pharmaceutical Sciences; 4Frontier Research Center for Genome and Drug Discovery, Tokyo University of Science, Noda, Chiba 278-8510; 5Cooperative Research Center of Life Sciences, Kobe-Gakuin University, Nishi-ku, Kobe, Hyogo 651-2180, Japan

Received July 6, 2006; Accepted August 30, 2006

Abstract. The in vitro relationship between the human p53 DNA binding domain (p53 DBD) and glycolipids was investigated. We isolated the glycolipid fraction from spinach (Spinacia oleracea L.) and found that the fraction inhibited the double-stranded DNA (dsDNA) binding activity of p53 DBD. Since the fraction contained mainly three glycolipids, monogalactosyl diacylglycerol (MGDG), digalactosyl diacylglycerol (DGDG) and sulfoquinovosyl diacylglycerol (SQDG), and each glycolipid was purified using silica gel column chromatography. Purified SQDG inhibited the activity, however, purified MGDG and DGDG had no influence. In this study, we demonstrated the structure-function relationship between chemically synthetic SQDG and p53 DBD. The major action is probably dependent on the fatty acid effect, although SQDG was a much stronger inhibitor than the fatty acid alone present in SQDG. The inhibitory activity of SQDG was weakened by the R248A mutant of p53 DBD, suggesting that R248 in the dsDNA binding site of p53 must be important for the inhibitory activity of SQDG. SQDG binding to p53 DBD could be reversed with a non-ionic detergent, Nonidet P-40.

This is the first study of a glycolipid, SQDG, acting as a dsDNA binding inhibitor of p53, and it could be considered that a SQDG-containing thylakoid membrane in plant chloroplasts might regulate the activity of p53 for cell division, cell cycle checkpoint and tumor suppression.

Introduction

The tumor suppressor protein p53 (393 amino acids) is a transcription factor that functions to maintain the integrity of the genome (1). On its induction in response to DNA damage, p53 promotes cell cycle arrest in G1 phase (2) and apoptosis if DNA repair is not possible (3). The p53 gene encodes a protein with a central DNA binding domain (DBD) comprised of residues 102-292, flanked by an N-terminal transactivation domain, and a C-terminal tetramerization domain (4). The crystal structure of the core domain (i.e., p53 DBD) bound to DNA has been determined (5). The crystal structure of the core domain consists of a large ß-sandwich that acts as a scaffold for three loop-based elements that contact the DNA (5). Importantly, the residues most frequently mutated in cancers are all at or near the protein-DNA interface, and over two-thirds of the missense mutations are within the DNA-binding loops (6). While it is clear that tumorigenic p53-DBD mutations act by diminishing the DNA binding activity of p53 (7,8), the mechanisms are not fully characterized.

We have been screening the natural compounds which inhibited the double-stranded DNA (dsDNA) binding activity of human p53 DBD, because inhibitors can elucidate the structure and function of p53. Recently, we found that the glycolipid fraction from spinach (Spinacia oleracea L.) was a potent inhibitor of p53 DBD activity. This fraction mainly contains the major glycolipids in the classes of monogalactosyl diacylglycerol (MGDG), digalactosyl diacylglycerol (DGDG) and sulfoquinovosyl diacylglycerol (SQDG). Subsequently, we investigated the effects on the inhibitory activity of p53 DBD against purified glycolipids from spinach, and the chemically synthesized the related compounds of the glycolipid. We found that SQDG binds or
interacts with p53 DBD and strongly suppresses its activity. In this study, we discuss the effects of SQDG on the activity of p53. This study of glycolipids may help to clarify the structure and function of p53-DBD.

Materials and methods

Materials. Spinach (Spinacia oleracea L.) was purchased in May, 2005 from a supermarket (Co-operative Union Co., Kobe, Hyogo prefecture, Japan). Diaion HP-20 was obtained from Mitsubishi Chemical Inc. (Tokyo, Japan). Supercoiled pBR322 plasmid dsDNA was obtained from Takara Bio Inc. (Kyoto, Japan). The glycolipid, SQDG, and its derivatives were chemically synthesized as described previously (9). All other reagents were of analytical grade and purchased from Nacalai Tesque (Kyoto, Japan).

Extraction and isolation of the glycolipid fraction from spinach. Water-soluble substances were extracted from dried spinach (50 g) with 1000 ml of warm water (60°C). The tissue cake was added to 1000 ml of warm ethanol (60°C), and the substances containing glycolipids were extracted. Ethanol extract (100%) was diluted with water to a 70% ethanol solution. The solution was subjected to Diaion HP-20 column chromatography (200 ml), a hydrophobic type of chromatography, washed with 1000 ml of 70% ethanol, and then eluted using increasing concentrations of methanol in ethyl acetate. Fractions A and B were concentrated and dissolved in a small volume of methanol/water (4/1, v/v), respectively. Fraction A was concentrated and dissolved in a small volume of ethyl acetate/methanol (2/1, v/v), and then applied to the same silica gel column. It was then successively eluted using increasing concentrations of acetone in ethyl acetate. Fractions A and B were identified from the spectral data and by comparison with literature data (10-13). SQDG was identified from the spectral data and by comparison with our data, which we have previously reported (9).

MGDG: 1H NMR (CDCl3, 600 MHz) δ 5.40-5.30 (13H, m), 4.40 (1H, dd, J = 11.9 Hz, 3.2 Hz), 4.28 (1H, d, J = 7.4 Hz), 4.21 (1H, dd, J = 11.9 Hz, 6.4 Hz), 4.01 (1H, brm), 3.98 (1H, dd, J = 12.2 Hz, 5.8 Hz), 3.91 (1H, dd, J = 11.3 Hz, 5.5 Hz), 3.86 (1H, dd, J = 12.2 Hz, 4.0 Hz), 3.73 (1H, m), 3.66 (1H, m), 3.60 (1H, dd, J = 9.3 Hz, 3.0 Hz), 3.55 (1H, m), 2.80 (8H, m), 2.32 (4H, m), 2.05 (8H, m), 1.61 (4H, m), 1.40-1.20 (16 H, m), 0.97 (6H, t, J = 7.6 Hz). 13C NMR (CDCl3-CD3OD, 100 MHz) δ 173.8, 173.4, 131.9, 130.1, 128.2, 128.1, 127.7, 127.0, 103.9, 74.8, 73.2, 71.3, 70.9, 70.3, 70.0, 69.9, 69.8, 68.7, 67.9, 62.9, 61.7, 61.9, 34.1, 34.0, 29.6, 29.3, 29.1, 29.0, 27.1, 25.5, 25.4, 24.7, 20.4, 14.1. IR (film) νmax 3422, 2924, 2855, 1737, 1459, 1071 cm⁻¹.

DGDG: 1H NMR (CDCl3, 600 MHz) δ 5.39-5.24 (13H, m), 4.43 (1H, dd, J = 12.1 Hz, 2.6 Hz), 4.23 (1H, dd, J = 12.0 Hz, 7.3 Hz), 4.23 (1H, d, J = 7.3 Hz), 3.93 (1H, dd, J = 10.1 Hz, 5.3 Hz), 3.86, 3.83 (2H, m), 3.74-3.66 (8H, m), 3.50 (1H, dd, J = 9.7 Hz, 7.3 Hz), 3.47 (1H, dd, J = 3.7 Hz, 3.1 Hz), 2.80 (8H, m), 2.31 (4H, m), 2.07 (8H, m), 1.60 (4H, m), 1.30-1.28 (16 H, m), 0.97 (6H, t, J = 7.6 Hz). 13C NMR (CDCl3-CD3OD, 100 MHz) δ 173.8, 173.4, 131.9, 130.1, 128.2, 128.1, 127.7, 127.0, 103.8, 99.4, 72.9, 72.5, 70.9, 70.3, 70.0, 69.9, 69.8, 68.7, 67.9, 66.0, 62.7, 61.8, 34.2, 34.0, 29.8, 29.6, 29.3, 29.1, 29.0, 27.1, 25.5, 25.4, 24.7, 22.5, 20.4, 14.1. IR (film) νmax 3404, 2924, 2855, 1740, 1653, 1461, 1261, 1074, 801, 696 cm⁻¹.

SQDG: 1H NMR (CDCl3-CD3OD, 600 MHz) δ 5.32 (1H, m), 4.41 (1H, m), 4.07 (2H, m), 3.64 (1H, m), 3.43 (2H, m), 1.44 (2H, m), 1.18 (2H, m), 0.89 (3H, m), 0.81 (3H, m), 0.78 (3H, m), 0.72 (3H, m). 13C NMR (CDCl3-CD3OD, 100 MHz) δ 207.4, 173.8, 173.4, 131.9, 130.1, 128.2, 128.1, 127.7, 127.0, 103.8, 99.4, 72.9, 72.5, 70.9, 70.3, 70.0, 69.9, 69.8, 68.7, 67.9, 66.0, 62.7, 61.8, 34.2, 34.0, 29.8, 29.6, 29.3, 29.1, 29.0, 27.1, 25.5, 25.4, 24.7, 22.5, 20.4, 14.1. IR (film) νmax 3404, 2924, 2855, 1740, 1653, 1461, 1261, 1074, 801, 696 cm⁻¹. The fraction containing SQDG was obtained in methanol/water (4/1, v/v), applied to a Sep-Pak C18 column, and eluted using increasing concentrations of methanol in water. The fraction containing SQDG was obtained in methanol/water (9/1, v/v).

\[\text{SQDG: 1H NMR (CDCl3-CD3OD, 600 MHz) δ 5.32 (1H, m), 4.41 (1H, m), 4.07 (2H, m), 3.64 (1H, m), 3.43 (2H, m), 1.44 (2H, m), 1.18 (2H, m), 0.89 (3H, m), 0.81 (3H, m), 0.78 (3H, m), 0.72 (3H, m). 13C NMR (CDCl3-CD3OD, 100 MHz) δ 207.4, 173.8, 173.4, 131.9, 130.1, 128.2, 128.1, 127.7, 127.0, 103.8, 99.4, 72.9, 72.5, 70.9, 70.3, 70.0, 69.9, 69.8, 68.7, 67.9, 66.0, 62.7, 61.8, 34.2, 34.0, 29.8, 29.6, 29.3, 29.1, 29.0, 27.1, 25.5, 25.4, 24.7, 22.5, 20.4, 14.1. IR (film) νmax 3404, 2924, 2855, 1740, 1653, 1461, 1261, 1074, 801, 696 cm⁻¹.}\]
Expression and purification of human p53 DBD. The human p53-DNA binding domain (p53 DBD) gene (residues 92-292) was cloned into pET28b between Ndel and XhoI sites. The histidine-tagged protein was overexpressed in Escherichia coli strain BL21(DE3) harboring the expression plasmid constructed in our laboratory. The expression vector of the mutant protein (i.e., R248A) was constructed by QuikChange site-directed mutagenesis kit (Stratagene) and fully sequenced. The mutant protein of p53-DBD was overexpressed in Escherichia coli strain BL21(DE3) harboring the expression plasmid pET28b. After Ni-NTA column (Qiagen) purification, following the procedure recommended by the manufacturer, the mutant proteins were purified on a heparin column (Amersham) by elution with a concentration gradient of 0-1 M potassium chloride.

Gel mobility shift assay. The gel mobility shift assay was carried out as described by Casas-Finet et al (14). The standard binding mixture (a final volume of 20 μl) contained 20 mM Tris-HCl, pH 7.5, 10% glycerol, 10% dimethyl sulfoxide, 1 mM EDTA, 0.20 pmol pBR322 dsDNA (i.e., 870 pmol nucleotide), and 30.0 pmol (1.50 μM) human p53 DBD. The mixture was incubated for 20 min on ice. Samples were run on 1.0% agarose gel in 0.1 M Tris-acetate, pH 8.3, containing 5 mM EDTA at 100 V for 1 h. The agarose gels were stained with ethidium bromide and dsDNA was visualized on a UV transilluminator. The gel mobility shift length of pBR322 dsDNA was measured with computer software (Zero-D scan, version 1.0, M&S Instruments Trading).

Results

Inhibitory effects of glycolipids from spinach on the dsDNA binding activity of human p53 DBD. We first established the assay method of dsDNA binding activity of human p53 DBD, which is the central region of p53, using agarose gel electrophoresis. As shown in Fig. 2, 30.0 pmol of p53 DBD bound to pBR322 dsDNA, and p53 DBD and dsDNA were complexed; therefore, the dsDNA stained with ethidium bromide was shifted to the upper side (lane 2). Since the same amount of BSA (bovine serum albumin) instead of p53 DBD did not shift at all (data not shown), dsDNA binding activity could occur selectively to a specific site on p53 DBD. The activity of p53 DBD was dose-dependent, and the distance of the stained and shifted band could be proportional to dsDNA binding activity. We decided the activity by the shifted distances of the band, and 30.0 pmol of p53 DBD (i.e., 1.50 μM, lane 2) was used in the experiments in this study.

As described in the Introduction, inhibitors of dsDNA-binding activity of human p53 DBD were screened from natural sources. We found that the glycolipid fraction from spinach (Spinacia oleracea L.) potently inhibited activity, and other fractions such as water-soluble and fat-soluble fractions from spinach had no influence. The glycolipid fraction (400 ng; i.e., 20 μg/ml) moderately inhibited the activity of purified SQDG (lanes 4 and 5), whereas purified SQDG completely inhibited the activity (lane 6). The inhibitory effect of purified SQDG was stronger than that of the same amount of the glycolipid fraction from spinach. These results suggested that SQDG in the glycolipid fraction must be an inhibitory compound of activity. Therefore, we concentrated SQDG and its derivatives, which were chemically synthesized, in the latter part of this study.

Inhibitory effects of synthetic SQDG and its derivatives on the activity of human p53 DBD. SQDG can be separated into four chemical parts: monosaccharide (i.e., D-glucose, Fig. 3D), a sulfate moiety (Group II), glycerol (Fig. 3F) (Group I), a sulfate moiety (Group III) and fatty acid(s) (i.e., stearic acid (C18:0), Fig. 3H) (Group IV). Since the method of chemical synthesis of SQDG succeeded previously (9), SQDG (Groups I-IV) was chemically synthesized, and purified SQDG, and these compounds were completely purified from the glycolipid fraction (400 ng; i.e., 20 μg/ml) moderately inhibited the dsDNA binding activity of human p53 DBD (lanes 4 and 5, respectively), whereas purified SQDG completely inhibited the activity (lane 6). The inhibitory effect of purified SQDG was stronger than that of the same amount of the glycolipid fraction from spinach. These results suggested that SQDG in the glycolipid fraction must be an inhibitory compound of activity.

Structural models of the complex. Molecular docking of human p53 DBD and a glycolipid, SQDG(C18:0) was performed using the Affinity program within Insight II software (Accelrys, San Diego, CA). The coordinates of human p53 DBD (Protein Data Bank (PDB) ID: 1TUP) were obtained from PDB. The initial position of SQDG(C18:0) was determined based on the result of the dsDNA gel mobility shift assay with mutant p53 DBD and the protein surface of the hydrophobicity. The calculation used a CVFF force field in the Discovery program (Accelrys).

Figure 2. Inhibition of the glycolipids from spinach on the dsDNA binding activity of human p53 DBD. Gel mobility shift assay of binding between pBR322 plasmid dsDNA (0.20 pmol; 870 pmol of nucleotide) and p53 DBD (30.0 pmol, lanes 2-6). Lane 1 contained no proteins. Lanes 3 to 6 contained 400 ng (20 μg/ml) of the glycolipid fraction, purified MGDG, purified DGDG, and purified SQDG, respectively. An ethidium bromide-stained gel is shown.

3.34 (1H, m), 3.15 (1H, m), 2.99 (4H, m), 2.34 (4H, m), 1.60 (4H, m), 1.28 (56H, brm), 0.89 (6H, m). The chemical structures of the three glycolipids (i.e., MGDG, DGDG and SQDG) are shown in Fig. 1.
The basic structures of synthesized SQDG [α-SQDG(C18:0)] are shown in Fig. 3A, consisting of two fatty acids [i.e., C18-saturated fatty acid, stearic acid (C18:0)]. Sulfoquinovosyl monoacylglycerol (SQMG), which consists of one fatty acid (Groups I-IV), was also synthesized [Fig. 3C, (α-SQMG (C18:0)). SQMG/SQDG could have stereoisomers of two configurations, α- or β-type, between sulfoquinovose (Groups I and II) and glycerol (Group III). SQDG/SQMG of α-configuration (Fig. 3A and C) is the natural type, and SQDG of β-configuration [Fig. 3B, (β-SQDG(C18:0))] is the unnatural type (9). Parts of SQDG compounds of such as D-glucose-6-sulfate (Fig. 3E) (Groups I and II) and 1,2-diacylglycerol (Fig. 3G) (Groups III and IV) were also prepared.

As shown in Fig. 4, 2.4 nmol (120 μM) of synthesized α-SQDG(C18:0) completely inhibited the dsDNA binding activity of human p53 DBD. β-SQDG(C18:0) also inhibited the activity to a similar extent as α-SQDG(C18:0), suggesting that the configuration is not essential for the inhibitory effect. D-glucose (monosaccharide, Group I), D-glucose-6-sulfate (monosaccharide with a sulfate moiety, Groups I and II), glycerol (Group III), and 1,2-diacylglycerol (Groups III and IV) showed no inhibitory effect.

Stearic acid (C18:0) (fatty acid, Group IV) moderately inhibited the activity of p53 DBD with 57% inhibition by 2.4 nmol of stearic acid (Fig. 4). The inhibitory effect of α-SQMG also inhibited activity; however, the inhibitory effect of α-SQMG was slightly weaker than that of α-SQDG(C18:0). These results suggested that fatty acid moiety and its number of SQDG/SQMG might be important for inhibition.

The sulfate moiety (Group II) in the monosaccharide was essential for inhibition, since neutral glycolipids such as MGDG and DGDG, consisting of Groups I, III and IV, showed no inhibitory effect (Fig. 2). On the other hand, 2.4 nmol of cholesterol sulfate inhibited the dsDNA activity of p53 DBD, and cholesterol had no influence on the activity at the same concentration (data not shown), suggesting that the sulfate moiety of the anionic lipids was important. The inhibitory effect was strongly influenced by partial change of the SQDG structure, suggesting that stronger inhibitory protocols for the

Figure 3. Chemically synthesized structures of derivatives and stereoisomers of SQDG. SQDG separated into four groups. Group I: Monosaccharide. Group II: 6-Sulfate moiety. Group III: Glycerol. Group IV: Fatty acid(s). (A) 1,2-di-O-acyl-3-O-(6-deoxy-6-sulfo-α-D-glucopyranosyl)sn-glycerol (α-SQDG(C18:0), Groups I-IV). (B) 1,2-di-O-acyl-3-O-(6-deoxy-6-sulfo-β-D-glucopyranosyl)sn-glycerol (β-SQDG(C18:0), Groups I-IV). (C) 1-mono-O-acyl-3-O-(6-deoxy-6-sulfo-α-D-glucopyranosyl)sn-glycerol (α-SQMG (C18:0), Groups I-IV). (D) D-glucose (Group I). (E) D-glucose-6-sulfate (Groups I and II). (F) Glycerol (Group III). (G) 1,2-Diacylglycerol (Groups III and IV). (H) Stearic acid (C18:0, Group IV).

Figure 4. Inhibition of synthesized SQDG and its derivatives (2.4 nmol each) on the dsDNA binding activity of human p53 DBD. The dsDNA binding activity of p53 DBD (30.0 pmol) in the absence of compounds was taken as 0%.
synthesis of new lipids containing sulfate (i.e., sulfolipids) are possible.

Effects of reaction conditions on \(\alpha\)-SQDG/SQMG inhibition. Fig. 5A shows the inhibition dose-response curves of \(\alpha\)-SQDG(C18:0) and \(\alpha\)-SQMG(C18:0) against human p53 DBD (30.0 pmol). Both \(\alpha\)-SQDG(C18:0) and \(\alpha\)-SQMG(C18:0) were effective at inhibiting the dsDNA binding activity of p53 DBD, with 50% inhibition observed at 0.18 nmol (9.0 \(\mu\)M) and 0.55 nmol (27.5 \(\mu\)M), respectively. The inhibitory effect of \(\alpha\)-SQDG(C18:0) was ~3-fold stronger than that of \(\alpha\)-SQMG (C18:0). The synthesized \(\beta\)-SQDG(C18:0), which is an unnatural stereoisomer of \(\alpha\)-SQDG(C18:0), inhibited to the same extent as \(\alpha\)-SQDG(C18:0), with 50% inhibition of 0.19 nmol (9.5 \(\mu\)M) (data not shown). Therefore, we concentrated \(\alpha\)-SQDG(C18:0), which was chemically synthesized, in the latter part of this study.

To determine the effects of a non-ionic detergent on the binding of \(\alpha\)-SQDG(C18:0) and human p53 DBD, Nonidet P-40 (NP-40) was added to the reaction mixture at various concentrations. The p53 DBD inhibitory effect of \(\alpha\)-SQDG (C18:0) at 0.60 nmol was significantly reversed by the addition of NP-40 to the reaction mixture (Fig. 5B). The inhibitory reversion by NP-40 was concentration dependent, and the reversion of 50% was found by the addition of 0.5% NP-40. This result suggested that the fatty acid moiety of \(\alpha\)-SQDG(C18:0) might interact with the hydrophobic region of p53 DBD protein.

We also tested whether an excess amount of a DNA analog, poly(rC) (2.00 pmol), or a protein, BSA (12.5 \(\mu\)M, 250 pmol), could prevent the inhibitory effects of \(\alpha\)-SQDG(C18:0). If \(\alpha\)-SQDG(C18:0) binds to p53 DBD by non-specific adhesion, the addition of a nucleic acid and/or protein would be expected to reduce inhibitory activity. The fact that neither poly(rC) nor BSA influenced the inhibitory effects of \(\alpha\)-SQDG(C18:0) suggests that the compound occurs selectively or binds to a specific site on p53 DBD and not to the nucleic acid.

Binding analysis of \(\alpha\)-SQDG(C18:0) and human p53 DBD. To determine whether SQDG resulted in binding to DNA or human p53 DBD, the interaction of SQDG with dsDNA was investigated based on the thermal transition of dsDNA with or without \(\alpha\)-SQDG(C18:0). The melting temperature (Tm) of dsDNA with an excess amount of \(\alpha\)-SQDG(C18:0) (100 \(\mu\)M) was measured using a spectrophotometer equipped with a thermoelectric cell holder. In the concentration range used, no thermal transition of Tm was observed, whereas when ethidium bromide, a typical intercalating compound, was used as a
positive control, it produced clear thermal transition (data not shown). The results indicated that this compound did not intercalate to dsDNA, and fatty acid might directly bind to p53 DBD and inhibit its activity.

To confirm direct binding between SQDG and human p53 DBD, the kinetic parameters for α-SQDG(C18:0) and binding were determined using p53 DBD immobilized to the sensor chip in a BIAcore. p53 DBD (565 pmol) was conjugated to the CM5 sensor chip, and α-SQDG(C18:0) was added to the conjugated proteins. The response differences for the binding of α-SQDG(C18:0) to the protein were ~200 RU, and this compound dissociated very slowly from p53 DBD. The dissociation constants (KD) of the binding of α-SQDG(C18:0) to the protein were determined to be 5.41 nM from these data. Kinetic studies supported the suggestion that α-SQDG(C18:0) interacted with p53 DBD directly.

Inhibitory effect of α-SQDG(C18:0) on the dsDNA binding activity of the mutant of human p53 DBD. Sequencing of the p53 gene in mammals, amphibians, birds, and fish has revealed five highly conserved domains, four of which fall within exons 5 through 8 (15): domain II (residues 117-142), domain III (residues 171-181), domain IV (residues 234-258), and domain V (residues 270-286). p53 is mutated in over half of all tumors. The overwhelming majority of these changes are found in the central DNA binding domain (i.e., p53 DBD) comprised of residues 94-312, which consists of domains II to V (5). Six tumorigenic mutations (R175, G245, R248, R249, R273 and R282) are most prevalent in the general population (5,16), and these positions account for 22% of the 15000 p53 mutations identified from human tumors and cell lines according to the database compiled by the Institut Curie (http://p53.free.fr/). In particular, R248 in domain IV is the most common mutation (17); therefore, an R248A mutant of human p53 DBD was prepared, and the inhibitory effect of fatty acids was investigated as compared with the wild-type.

Fig. 6 shows the inhibition dose-response curves of α-SQDG(C18:0) against the wild-type and R248A mutant of human p53 DBD (30.0 pmol). The compound was effective at inhibiting the dsDNA binding activity of both wild-type and mutant p53 DBD, although inhibition of the activity of mutant p53 DBD by α-SQDG(C18:0) was 1.77-fold weaker than that of the wild-type. These results suggested that α-SQDG(C18:0) must bind to or interact with R248 on the dsDNA binding surface of p53 DBD.

Simulation of the docking of human p53 DBD with α-SQDG (C18:0). As described above, the three-dimensional structure of human p53 DBD with or without chemically synthesized SQDG, α-SQDG(C18:0), was studied (Fig. 7). The crystal structure of human p53 DBD in complex with consensus dsDNA is shown in Fig. 7A. A large immunoglobulin-like β-sandwich, forming a compact barrel-like structure, provides the basic scaffold for the conserved DNA binding surface (the blue area of p53 DBD in Fig. 7). This extended surface, rich in basic amino acids, consists of a loop-sheet-helix motif and two large loops (L2 and L3).
The α-SQDG(C18:0) binding site of p53 DBD was refined using Insight II/Discovery (Accelrys) (Fig. 7B). A cavity (29 Å long, 8 Å wide and 3 Å high, respectively) where SQDG with two stearic acids (C18:0) can bind was searched for on the surface of the protein, and found in the hydrophobic area. α-SQDG(C18:0) was suggested to interact with the hydrophobic region of p53 DBD, because the complex of α-SQDG (C18:0) and p53 DBD was reversed by a neutral detergent, NP-40 (Fig. 5B). In these simulation results, the sulfate moiety of α-SQDG(C18:0) on p53 DBD was in the same position as the minor groove of dsDNA on p53 DBD, because the free sulfate group of α-SQDG(C18:0) was required for the inhibition of dsDNA binding activity (Fig. 4). Furthermore, the inhibitory effect of the compound on the R248A mutant of p53 DBD was weaker than on the wild-type (Fig. 6), the acidic group of the sulfate moiety of SQDG could interact with the basic residue of R248, and the alkyl chain region of the fatty acid moiety of SQDG interacted with the hydrophobic surface of p53. It was suggested that SQDG bound to the residue of R248 of p53 DBD and inhibited dsDNA binding activity by competing with dsDNA. Since the inhibitory effects of β-SQDG(C18:0), which is a stereoisomer of α-SQDG (C18:0) and synthetic compound, on the dsDNA binding activity of both wild-type and mutant p53 DBD was as strong as those of α-SQDG(C18:0), it could be considered that β-SQDG(C18:0) binding pockets in p53 DBD could be in the same position as the α-SQDG(C18:0) binding region. The size of the pockets may be a key to explain these inhibition characteristics by the length of SQDG fatty acids. This is the first study to find that SQDG could bind to human p53 directly, and inhibit or regulate the dsDNA binding activity of p53.

Discussion

The lipid composition of thylakoid membranes is highly conserved among higher plants, algae, and cyanobacteria, comprised mainly of the following three glycolipids, MGDG, DGDG, and SQDG (18). MGDG and DGDG are noncharged lipids, whereas SQDG possesses a negatively charged head group. Thylakoid membranes in plant chloroplasts and cyanobacterial cells are unique in possessing photosynthetic electron transport and photophosphorylation systems for the conversion of light to chemical energy. A mutant of Chlamydomonas reinhardtii, defective in SQDG (hf-2), showed photosystem II (PSII) activity that was 40% lower than that of the wild-type, an increase in sensitivity of the PSII activity to 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), and a lower growth rate of PSII activity that was 40% lower than that of the wild-type, (19-22). In accordance with these observations, the incubation of bacterial cells are unique in possessing photosynthetic electron transport and photophosphorylation systems for the conversion of light to chemical energy. A mutant of Chlamydomonas reinhardtii, defective in SQDG (hf-2), showed photosystem II (PSII) activity that was 40% lower than that of the wild-type, an increase in sensitivity of the PSII activity to 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), and a lower growth rate. An increase in sensitivity of the PSII activity to 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), and a lower growth rate of an increase in sensitivity of the PSII activity to 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), and a lower growth rate of syntheses of sulfoquinovosylocylglycerols, inhibitors of eukaryotic DNA polymerase α and β. Bioorg Med Chem 9: 367-376, 2001.

References


